Clinical Trial Update: Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TEV-45779 with Xolair (omalizumab) in adults with chronic idiopathic urticaria has completed and posted results on 2025-10-07. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Urticaria
• Urticaria

Drugs mentioned

• TEV-45779
• Xolair (omalizumab)

Snippet

Sponsor: Teva Pharmaceuticals USA | Conditions: Chronic Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2025-10-07